Anti-Human HER-2 (Trastuzumab)

Antibody Details

Product Details

Reactivity Species

Human

Host Species

Human

Expression Host

HEK-293

FC Effector Activity

Active

Immunogen

Human epidermoid carcinoma cells (A431) over-expressing EGFR.

Product Concentration

≥ 5.0 mg/ml

Endotoxin Level

≤ 1.0 EU/mg as determined by the LAL method

Purity

≥95% monomer by analytical SEC

Formulation

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Product Preparation

Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Pathogen Testing

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Storage and Handling

Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Regulatory Status

Research Use Only (RUO). Non-Therapeutic.

Country of Origin

USA

Shipping

Next Day 2-8°C

RRID

AB_2893910

Applications and Recommended Usage?
Quality Tested by Leinco

FC The suggested concentration for Trastuzumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 μg per 10⁶ cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.

Other Applications Reported In Literature ?

ELISA
IHC
CyTOF®

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Trastuzumab. Clone 4D5-8 recognizes human erbB-2. This product is for research use only.

Antigen Distribution

Ubiquitous expression with highest expression levels found in the kidney, skin, esophagus, and small intestine.

Background

Trastuzumab is a monoclonal antibody targeting HER2, a 185 kDa transmembrane glycoprotein that contains an extracellular domain and intracellular tyrosine kinase activity. When it is functioning normally, the HER2 pathway supports cell growth and division. On the other hand, the over expression of HER2 propels cell growth beyond its typical range. This overexpression is associated with some cancers, namely breast and stomach, in which the HER2 protein can be expressed up to 100 times more than in typical cells. Trastuzumab induces an immune-mediated response that triggers the internalization and downregulation of HER2 making it an excellent target for immunotherapy. Several clinical studies are under way which show that anti-HER-2/neu antibodies inhibit the growth and proliferation of these tumor cells In vitro as well as In vivo.

Antigen Details

Protein

HER-2/neu

PubMed

HER-2/neu

NCBI Gene Bank ID

2064

UniProt.org

Information on Uniprot.org

References & Citations

1. Fendly, B. et al. (1990) Cancer Research 50: 1550-1558.

2. McBride, H. et al. (2019) Pharm Res. 36(12): 177.

3. Zielinski, C. et al. (1997) Int. J. Cancer 73: 875–879

4. Valone, FH. et al. (1995) J. Clin. Oncology 13 (9): 2281-92.

5. Hynes, NE. et al. (1993) Br J Cancer. 68(6): 1140–1145.

Technical Protocols